Cysteine protease cathepsin F is expressed in human atherosclerotic lesions, is secreted by cultured macrophages, and modifies low density lipoprotein particles in vitro.
During atherogenesis, low density lipoprotein (LDL) particles in the arterial intima become modified and fuse to form extracellular lipid droplets. Proteolytic modification of apolipoprotein (apo) B-100 may be one mechanism of droplet formation from LDL. Here we studied whether the newly described acid protease cathepsin F can generate LDL-derived lipid droplets in vitro. Treatment of LDL particles with human recombinant cathepsin F led to extensive degradation of apoB-100, which, as determined by rate zonal flotation, electron microscopy, and NMR spectroscopy, triggered both aggregation and fusion of the LDL particles. Two other acid cysteine proteases, cathepsins S and K, which have been shown to be present in the arterial intima, were also capable of degrading apoB-100, albeit less efficiently. Cathepsin F treatment resulted also in enhanced retention of LDL to human arterial proteoglycans in vitro. Cultured monocyte-derived macrophages were found to secrete active cathepsin F. In addition, similarly with cathepsins S and K, cathepsin F was found to be localized mainly within the macrophage-rich areas of the human coronary atherosclerotic plaques. These results suggest that proteolytic modification of LDL by cathepsin F may be one mechanism leading to the extracellular accumulation of LDL-derived lipid droplets within the proteoglycan-rich extracellular matrix of the arterial intima during atherogenesis.
Oörni
Katariina
K
Wihuri Research Institute, Kalliolinnantie 4, FIN-00140 Helsinki, Finland. kati.oorni@wri.fi
Sneck
Mia
M
Brömme
Dieter
D
Pentikäinen
Markku O
MO
Lindstedt
Ken A
KA
Mäyränpää
Mikko
M
Aitio
Helena
H
Kovanen
Petri T
PT
D000818:Animals; D001011:Aorta / Q000473:pathology; D053299:Apolipoprotein B-100; D001055:Apolipoproteins B / Q000378:metabolism; D001161:Arteriosclerosis / Q000378:metabolism*; D015153:Blotting, Western; D056646:Cathepsin F; D056657:Cathepsin K; D002403:Cathepsins / Q000096:biosynthesis* / Q000378:metabolism; D002417:Cattle; D002474:Cell-Free System; D002478:Cells, Cultured; D003331:Coronary Vessels / Q000378:metabolism; D003546:Cysteine Endopeptidases / Q000378:metabolism; D005109:Extracellular Matrix / Q000378:metabolism; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007150:Immunohistochemistry; D008077:Lipoproteins, LDL / Q000378:metabolism*; D008264:Macrophages / Q000378:metabolism*; D009682:Magnetic Resonance Spectroscopy; D008854:Microscopy, Electron; D008856:Microscopy, Fluorescence; D009000:Monocytes / Q000378:metabolism; D011509:Proteoglycans / Q000378:metabolism; D012333:RNA, Messenger / Q000378:metabolism; D013997:Time Factors
D053299:Apolipoprotein B-100; D001055:Apolipoproteins B; D008077:Lipoproteins, LDL; D011509:Proteoglycans; D012333:RNA, Messenger; D002403:Cathepsins; D003546:Cysteine Endopeptidases; C028217:cathepsin S; C534130:CTSK protein, human; D056657:Cathepsin K; C534090:CTSF protein, human; D056646:Cathepsin F